HS2
General Information
DCTPep ID DCTPep01043
Peptide Name HS2
Sequence CGAISLAPKLQIKES
Sequence Length 15
UniProt ID Not available
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
ACP Tumor active peptide Cancer targeted peptides
Activity Information
Cell Line | Disease | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|
CT26 | Mouse colon adenocarcinoma | IC50=93.5±10.7 µM | MTT assay | 24, 48, 72h | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target programmed cell death protein 1
Affinity Not available
Mechanism Not available
Structure Information
PDB ID Not available
Predicted Structure DCTPep01043
(Please note that there is the predicted structure, predicted by AlphaFold)
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C68H120N18O21S1
Absent amino acids DFHMNRTVWY
Theoretical pI 8.20
Acidic residues 1
Basic residues 2
Polar residues 4
Molecular weight (Average) 1557.87
Molecular weight (Monoisotopic) 1556.86
Common amino acids AIKLS
Net charge 1
Instability index (II) 39.77
Aliphatic index 117.33
Grand average of hydropathicity (GRAVY) 0.287
Half Life
1.2 hours (mammalian reticulocytes, in vitro).
>20 hours (yeast, in vivo).
>10 hours (Escherichia coli, in vivo).
Extinction coefficients
Ext. coefficient 0
Abs 0.1% (=1 g/l) 0.000, assuming all pairs of Cys residues form cystines
Ext. coefficient 0
Abs 0.1% (=1 g/l) 0.000, assuming all Cys residues are reduced
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 33360579
Title Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy
Year 2021
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available